The content on this site is intended for healthcare professionals only
Prof Stephen Johnston speaks on treatment of breast cancer and advanced breast cancer with aromotase inhibitors, tamoxifen, fulvestrant and previous trials using endocrine therapy at EBCC 8.
Prof Johnston highlights the need for selecting patients in these trials that will benefit from the trials as many only extend progression free survival by three to four months.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert round up July 28th to August 3rd, 2023
CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC
Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Loco-regional management after neoadjuvant chemotherapy
Personalised risk-stratified breast cancer screening for BRCA germline mutations and other genes
Elacestrant shows improved PFS in ER-positive/HER2-negative mBC
